Insider Transactions in Q3 2025 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2025
|
A. Sinclair Dunlop |
SELL
Other acquisition or disposition
|
Indirect |
3,837
-11.29%
|
-
|
|
Sep 30
2025
|
A. Sinclair Dunlop |
SELL
Open market or private sale
|
Indirect |
31,092
-47.78%
|
$684,024
$22.58 P/Share
|
|
Sep 19
2025
|
A. Sinclair Dunlop |
SELL
Other acquisition or disposition
|
Indirect |
3,837
-5.57%
|
-
|
|
Sep 19
2025
|
A. Sinclair Dunlop |
SELL
Open market or private sale
|
Indirect |
31,092
-31.09%
|
$684,024
$22.95 P/Share
|
|
Sep 16
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-4.04%
|
$120,000
$24.34 P/Share
|
|
Sep 15
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
189
-0.35%
|
$4,536
$24.19 P/Share
|
|
Sep 10
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Indirect |
20,000
-28.52%
|
$520,000
$26.17 P/Share
|
|
Sep 08
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-14.21%
|
$270,000
$27.83 P/Share
|
|
Sep 08
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,729
-22.78%
|
$883,683
$27.86 P/Share
|
|
Sep 08
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+9.45%
|
$150,000
$10.03 P/Share
|
|
Sep 02
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
548
-1.01%
|
$15,344
$28.08 P/Share
|
|
Sep 02
2025
|
Kelley Boucher Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,476
+23.78%
|
-
|
|
Aug 28
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
49,963
-13.96%
|
$1,398,964
$28.39 P/Share
|
|
Aug 27
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
175,037
-32.84%
|
$4,901,036
$28.19 P/Share
|
|
Aug 26
2025
|
Leslie Meltzer Chief Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
61,804
+50.0%
|
-
|
|
Aug 18
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-3.88%
|
$135,000
$27.8 P/Share
|
|
Jul 17
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,725
-5.61%
|
$394,500
$20.21 P/Share
|
|
Jul 17
2025
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,997
+2.5%
|
$35,988
$4.31 P/Share
|
|
Jul 16
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-3.74%
|
$95,000
$19.55 P/Share
|
|
Jul 15
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,900
-0.55%
|
$38,000
$20.09 P/Share
|
|
Jul 15
2025
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+0.23%
|
$3,200
$4.31 P/Share
|
|
Jul 14
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
137,465
-28.59%
|
$2,749,300
$20.19 P/Share
|
|
Jul 14
2025
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
65,203
+11.94%
|
$260,812
$4.31 P/Share
|